Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2. Cita con resumen
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44. [Ref.ID 100972]
3.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
4.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
5.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
6.
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (CC) . Eur Heart J 2015;36:1012-22. [Ref.ID 98806]
7. Cita con resumen
Jenkins DJA, Kendall CWC, Vuksan V, Faulkner D, Augustin LSA, Mitchell S, Ireland C, Srichaikul K, Mirrahimi A, Chiavaroli L, Mejia SB, Nishi S, Sahye-Pudaruth S, Patel D, Bashyam B, Vidgen E, de Souza RJ, Sievenpiper JL, Coveney J, Josse RG, Leiter LA. Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial. Diabetes Care 2014;37:1806-14. [Ref.ID 97658]
8.Tiene citas relacionadas Cita con resumen
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. [Ref.ID 96330]
10.
Schwartz GG, Olsson AG, Abt M, Mallantyne CM, Barter PJ, Brumm J, Chatman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundi H, Nicholis SJ, Shah PK, Tardif JC, Wright RS, for the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99. [Ref.ID 94165]
11.Tiene citas relacionadas Cita con resumen
McBrien K, Rabi DM, Campbell N, Bamieh L, Clement F, Hemmelgam BR, Tonelli M, Leiter LA, Klarenbach SW, Manns BJ. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012;172:1296-303. [Ref.ID 93794]
12. Cita con resumen
Jenkins DJA, Jones PJH, Lamarche B, Kendall CWC, Faulkner D, Cermakova L, Gigleux I, Ramprasath V, de Souza R, Ireland C, Patel D, Srichaikul K, Abdulnoour S, Bashyam B, Collier C, Hoshizaki S, Josse RG, Leiter LA, Connelly PW. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of Intensity of dietary advice on serum lipids in hyperlipidemia . JAMA 2011;306:831-9. [Ref.ID 91008]
13.Tiene citas relacionadas
Jenkins DJA, Kendall CWC, Marchie A, Faulkner D, Wong JMW, de Souza R, Emam A, Parker T L, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering food vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502-10. [Ref.ID 66991]
Seleccionar todas
 
 1 a 13 de 13